Donanemab : New Alzheimer’s Drug
A new Alzheimer’s drug, donanemab, has received support from an FDA advisory committee, moving closer to approval.
- Intended for early-stage Alzheimer’s, it shows significant slowing of cognitive decline.
- The drug works by targeting amyloid beta protein deposits in the brain.
- Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and is the most common type of dementia.
- It’s characterized by changes in the brain that lead to protein deposits, brain shrinkage, and eventually cell death.
